DE2336199A1 - Radioaktive xenonloesung - Google Patents
Radioaktive xenonloesungInfo
- Publication number
- DE2336199A1 DE2336199A1 DE19732336199 DE2336199A DE2336199A1 DE 2336199 A1 DE2336199 A1 DE 2336199A1 DE 19732336199 DE19732336199 DE 19732336199 DE 2336199 A DE2336199 A DE 2336199A DE 2336199 A1 DE2336199 A1 DE 2336199A1
- Authority
- DE
- Germany
- Prior art keywords
- xenon
- solution
- radioactive
- natural
- isotope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052724 xenon Inorganic materials 0.000 title claims description 93
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 title claims description 93
- 230000002285 radioactive effect Effects 0.000 title claims description 50
- 239000000243 solution Substances 0.000 claims description 54
- 239000007864 aqueous solution Substances 0.000 claims description 40
- FHNFHKCVQCLJFQ-NJFSPNSNSA-N Xenon-133 Chemical group [133Xe] FHNFHKCVQCLJFQ-NJFSPNSNSA-N 0.000 claims description 39
- 229940106670 xenon-133 Drugs 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 229960003267 xenon (127xe) gas Drugs 0.000 claims description 9
- FHNFHKCVQCLJFQ-AHCXROLUSA-N xenon-127 Chemical group [127Xe] FHNFHKCVQCLJFQ-AHCXROLUSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 150000001805 chlorine compounds Chemical class 0.000 claims 1
- 239000007789 gas Substances 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 229920001971 elastomer Polymers 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000013077 target material Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 2
- JFALSRSLKYAFGM-OIOBTWANSA-N uranium-235 Chemical compound [235U] JFALSRSLKYAFGM-OIOBTWANSA-N 0.000 description 2
- -1 xenon-129m Chemical compound 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- FHNFHKCVQCLJFQ-DBXDQKISSA-N xenon-122 Chemical compound [122Xe] FHNFHKCVQCLJFQ-DBXDQKISSA-N 0.000 description 1
- FHNFHKCVQCLJFQ-VENIDDJXSA-N xenon-125 Chemical compound [125Xe] FHNFHKCVQCLJFQ-VENIDDJXSA-N 0.000 description 1
- FHNFHKCVQCLJFQ-IGMARMGPSA-N xenon-131 Chemical compound [131Xe] FHNFHKCVQCLJFQ-IGMARMGPSA-N 0.000 description 1
- FHNFHKCVQCLJFQ-RNFDNDRNSA-N xenon-135 Chemical compound [135Xe] FHNFHKCVQCLJFQ-RNFDNDRNSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1206—Administration of radioactive gases, aerosols or breath tests
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Atmospheric Sciences (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27309572A | 1972-07-19 | 1972-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2336199A1 true DE2336199A1 (de) | 1974-02-07 |
Family
ID=23042536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732336199 Pending DE2336199A1 (de) | 1972-07-19 | 1973-07-17 | Radioaktive xenonloesung |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US3791982A (cs) |
| JP (1) | JPS4980231A (cs) |
| AU (1) | AU5826073A (cs) |
| BE (1) | BE802399A (cs) |
| DE (1) | DE2336199A1 (cs) |
| FR (1) | FR2264559A1 (cs) |
| GB (1) | GB1400132A (cs) |
| IT (1) | IT995041B (cs) |
| NL (1) | NL7309758A (cs) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5312592A (en) * | 1990-06-13 | 1994-05-17 | Scanditronix Ab | Disposable kit for preparation |
| US5494469A (en) * | 1994-09-30 | 1996-02-27 | The United States Of America As Represented By The Secretary Of The Navy | Inflatable life vest |
-
1972
- 1972-07-19 US US00273095A patent/US3791982A/en not_active Expired - Lifetime
-
1973
- 1973-07-04 GB GB3183273A patent/GB1400132A/en not_active Expired
- 1973-07-12 NL NL7309758A patent/NL7309758A/xx unknown
- 1973-07-12 FR FR7325646A patent/FR2264559A1/fr active Pending
- 1973-07-16 BE BE133527A patent/BE802399A/xx unknown
- 1973-07-17 DE DE19732336199 patent/DE2336199A1/de active Pending
- 1973-07-18 AU AU58260/73A patent/AU5826073A/en not_active Expired
- 1973-07-19 IT IT26763/73A patent/IT995041B/it active
- 1973-07-19 JP JP48080518A patent/JPS4980231A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NL7309758A (cs) | 1974-01-22 |
| FR2264559A1 (cs) | 1975-10-17 |
| JPS4980231A (cs) | 1974-08-02 |
| AU5826073A (en) | 1975-01-23 |
| GB1400132A (en) | 1975-07-16 |
| BE802399A (fr) | 1973-11-16 |
| IT995041B (it) | 1975-11-10 |
| US3791982A (en) | 1974-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3115053C2 (de) | Radioaktive Verbindungen enthaltende Kapseln und Verfahren zum Füllen derselben | |
| DE2826833A1 (de) | Nachladbares radioisotopengeneratorsystem und versandabschirmung zum nachladen eines radioisotopengenerators | |
| DE3237573A1 (de) | Technetium-99m-tri- und tetraphosphonate zur szintigraphischen dastellung res-haltiger organe und der lymphgefaesse und verfahren zu deren herstellung | |
| DE2207309C3 (de) | Isotopengenerator | |
| DE69524976T2 (de) | Herstellung von [11C] Methyljodid | |
| DE2519005A1 (de) | Verfahren zur diagnostischen sichtbarmachung von neoplastischen geweben | |
| DE2534985A1 (de) | Verfahren zum markieren mit 99 m technetium | |
| DE2434277A1 (de) | Verfahren zum herstellen von kapseln, die gasfoermige radioisotope enthalten | |
| DE2336199A1 (de) | Radioaktive xenonloesung | |
| DE2343641C2 (de) | Vorrichtung zum Einführen eines gasförmigen Radioisotops in einen Patienten, eine Kapsel zur Verwendung in einer derartigen Vorrichtung und eine Einheit zum sicheren Verpacken der Kapsel | |
| EP4323018B1 (de) | Herstellung von radiopharmaka für unterschiedliche anwendungszeitpunkte | |
| DE2419310C3 (de) | Verwendung von Tc-99m-Komplexen | |
| DE2746766A1 (de) | Verfahren zum behandeln einer blutprobe und kapillarroehrchen fuer die verwendung in diesem verfahren | |
| DE19809960C2 (de) | Verfahren zur Herstellung von [·1··5·O]Butanol und Vorrichtung zur Durchführung des Verfahrens | |
| DE2327870C2 (de) | Verfahren zur Herstellung eines mit 99↑m↑ Tc markierten Phosphat-Zinn-Komplexes zur Szintigraphie | |
| DE2427659C3 (de) | Verfahren zur Herstellung von radioaktiv markierten Erythrozyten | |
| DE2160009A1 (de) | Verfahren und Vorrichtung zur Herstellung eines injizierbaren Trägers für Radioisotope | |
| EP0003041B1 (de) | Technetium-99m-markiertes Diagnostikum zur Darstellung des retikuloendothelialen Systems (RES) und Verfahren zu seiner Herstellung | |
| DE2140177A1 (de) | Oral applizierbare, radioaktives jod enthaltende kapsel zur schilddruesenfunktionsdiagnostik und verfahren zu ihrer herstellung | |
| DE2922118C2 (cs) | ||
| EP3837230A1 (de) | Verfahren und vorrichtung zur hydrierung und hyperpolarisierung von tracer-molekülen für die magnetresonanzbildgebung | |
| CH645019A5 (de) | Loesungsmittelgemisch und verfahren zur herstellung von parenteral verabreichbaren injektionsloesungen. | |
| DE2607680C2 (cs) | ||
| DE2511712C3 (de) | Herstellung eines Technetium-99m-Generators | |
| DE2358123A1 (de) | Infusionsmaterial und verfahren zu seiner herstellung |